PT  - JOURNAL ARTICLE
AU  - Parra-A, Nicolás
AU  - Vargas-Calderón, Vladimir
AU  - Sebastián Flórez, Juan
AU  - Ardila, Leonel
AU  - Viviescas, Carlos
TI  - Percentage of reported Covid-19 cases in Colombia: Estimating the true scale of the pandemic
AID  - 10.1101/2020.12.30.20249052
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.30.20249052
4099  - http://medrxiv.org/content/early/2021/03/19/2020.12.30.20249052.short
4100  - http://medrxiv.org/content/early/2021/03/19/2020.12.30.20249052.full
AB  - At the outbreak of a virus, data on cases is sparse and commonly severe cases, with a higher probability of a fatal resolution, are detected at a larger rate than mild cases. In addition, in an under-sampling situation, the number of total cases is under-estimated leading to a biased case fatality rate estimation, most likely inflating the virus mortality. In this communication, we present a method to estimate the sub-report in a country that accounts for both the delay time between symptoms onset to death and the country’s demographics. The method is based on the comparison of the corrected case fatality rate (CFR) of the target country with the one of a benchmark country. Using reported data from Instituto Nacional de Salud up to December 28, we utilize our method to provide a comprehensive estimate of the Covid-19 sub-report in Colombia, its regions and some of its cities during 2020.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNo clinical trials were performedFunding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Brain Technologies Phone +57 318 407 9118All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe developed a Python library that eases the extraction, load and transformation of raw data from the INS database. The code is freely available at https://gitlab.com/hubrain/covid19. Also, we designed a dashboard were we keep a daily record of how reporting percentages are changing at each region which can be found at http://covid19.hubrain.co. Furthermore, the code to reproduce the figures and tables here presented is in https://gitlab.com/hubrain/covid19-paper. https://gitlab.com/hubrain/covid19-paper